## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.6% below STRENGTH zone (3.0-6.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($72.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Ionis to hold third quarter 2023 financial results webcast**
- Source: GuruFocus | 20251215T090920 | Neutral | Relevance: 100%
- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced it will host a live webcast on Thursday, November 2nd at 11:30 a.m. Eastern Time to discuss its third quarter 2023 financial results. The webcast will be accessible via its investor relations website, with a replay available for a limited time. Ionis is a leader in RNA-targeted therapy, with four marketed medicines and a strong late-stage pipeline in cardiovascular and neurological franchises.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $95 | $82 | +16% |
| 2025-12-15 | Leerink Partner | $100 | $85 | +18% |
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-15 | Leerink Partner | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 20 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Valuation stretched: PEG 25.7x requires aggressive growth execution.
3. Elevated short interest (12.7%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 3 raises (avg +15%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (3 raises, avg +15%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.5B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 12.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -2.6% to -0.6% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.56x) but short-term weakness (below SMA20). MACD histogram bearish (-0.69), momentum weakening. RSI neutral at 48. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.57% (CS: 24) | Neutral |
| RSI_14 | 47.7 | Neutral |
| MACD Histogram | -0.69 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.561x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.08
- **Stop Loss:** $72.16 (6.4% risk)
- **Target:** $82.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 219
- **Position Value:** $16,880.52
- **Portfolio %:** 16.88%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*